Miriam Merad, M.D.; Ph.D. is a Professor of Oncological Science, Medicine (Hem/Onc division) and Immunology and a member of the Immunology Institute and The Tisch Cancer Institute at the Mount Sinai School of Medicine in New York. Dr. Merad obtained her M.D. at the University of Algiers, Algeria. She did her residency in Hematology and Oncology in Paris, France and obtained her Ph.D. in Immunology in collaboration between Stanford University and University of Paris VII. She was recruited to Mount Sinai in 2004 and was promoted to the rank of Associate Professor with Tenure in 2007 and to Full Professor in 2010 and obtained an Endowed Chair in Cancer Immunology in 2014.
In 2010 Dr. Merad became the program leader of the Cancer Immunology Immunotherapy group at The Tisch Cancer Institute and the director of the Human Immunomonitoring Center.
Dr. Merad’s laboratory studies the mechanisms that regulate the development and function of the mononuclear phagocyte lineage including dendritic cells and macrophages. Her laboratory has made seminal discoveries in macrophage biology revealing their embryonic origin and their local maintenance in situ. Dr. Merad identified many of the mechanisms that control dendritic cells and macrophage development, homeostasis and function in different tissues including the contribution of mononuclear phagocytes to neuronal function, barrier tissue integrity and tumor response to immunotherapy. Dr. Merad belongs to several NIH funded scientific consortia including the mucosal immunology study team and the Immgen Consortia to decipher the transcriptional regulation of the tissue dendritic cell and macrophage lineage. Currently, one of the major goals of her laboratory is to identify the contribution of phagocytes to tumor progression and response to treatment in mice and humans.
Dr. Merad has authored more than 150 primary papers and reviews in high profile journals and has obtained extensive NIH funding for her studies on innate immunity in mice and humans.